Policy / Pricing EFPIA report adds to pressures on EU drug pricing policy PharmaphorumPharma trade body EFPIA says access to new medicines is worsening across Europe, as it makes the socioeconomic case for spending more on novel drugs.Read full story pharminent June 24, 2026 (Last updated: June 24, 2026) Pharmaphorum Pharma trade body EFPIA says access to new medicines is worsening across Europe, as it makes the socioeconomic case for spending more on novel drugs. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: CARsgen’s Satri-cel Wins World-First CAR-T Approval for Solid TumorNext: Boehringer and Combotope partner for cancer antibodies Related Stories Policy / Pricing Germany approves healthcare costs overhaul despite significant pharma opposition pharminent July 13, 2026 Policy / Pricing Decoding Medicare Advantage Coding Intensity pharminent July 1, 2026 Policy / Pricing UK partners with Eli Lilly on obesity plan pharminent June 29, 2026
